Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and mitomycin

cyc 202 has been researched along with mitomycin in 4 studies

Compound Research Comparison

Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010)
(cyc 202)		Studies
(mitomycin)		Trials
(mitomycin)		Recent Studies (post-2010) (mitomycin)
979739312,8931,7382,808

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
David-Pfeuty, T1
David-Pfeuty, T; Hernandez-Verdun, D; Nouvian-Dooghe, Y; Roussel, P; Sirri, V1
Fischer, K; Hescheler, J; Sauer, H; Wartenberg, M1

Other Studies

4 other study(ies) available for cyc 202 and mitomycin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    Oncogene, 1999, Dec-09, Volume: 18, Issue:52

    Topics: Blotting, Western; Breast Neoplasms; Carcinoma; CDC2-CDC28 Kinases; Cell Cycle; Cell Death; Cell Line; Cell Line, Transformed; Cell Nucleolus; Cell Nucleus; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; G1 Phase; Humans; Inhibitory Concentration 50; Kinetin; Mitomycin; Nucleic Acid Synthesis Inhibitors; Nucleolin; Phosphoproteins; Protein Serine-Threonine Kinases; Purines; RNA-Binding Proteins; Roscovitine; Tumor Cells, Cultured; Tumor Suppressor Protein p53

1999
Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells.
    Oncogene, 2001, Sep-20, Volume: 20, Issue:42

    Topics: Casein Kinase II; CDC2-CDC28 Kinases; Cell Cycle; Cell Line; Cell Nucleolus; Cell Nucleus; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Dichlororibofuranosylbenzimidazole; Enzyme Inhibitors; Gene Expression Regulation; Humans; Mitomycin; Models, Biological; Protein Serine-Threonine Kinases; Purines; Ribosomes; RNA, Ribosomal; Roscovitine; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2001
Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors.
    Biochimica et biophysica acta, 2002, Feb-13, Volume: 1589, Issue:1

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Male; Mimosine; Mitomycin; Prostatic Neoplasms; Purines; Roscovitine; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Proteins

2002